June 2019 - Volume 3 - Issue - Contributor Index

Alphabetical Search
Author:
't Hoen, P.
Author:
't Hoen, P. A.

COMPREHENSIVE DIAGNOSTICS OF ACUTE MYELOID LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING: PF262

Griffioen, M.; Arindrarto, W.; Borràs, D. M.; More

HemaSphere. 3:83, June 2019.

Author:
A, A.-L. M

SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB-OZOGAMICIN: PB2230

López-Pereira, P.; Figuera, Á.; Ormazábal, I.; More

HemaSphere. 3:999-1000, June 2019.

Author:
Aapro, M.
Author:
Ababou, M.
Author:
Abadi, U.
Author:
Abagiu, A.
Author:
Abáigar, M.

MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: PF533

Martín-Izquierdo, M.; López-Cadenas, F.; del Real, Sánchez J.; More

HemaSphere. 3:219-220, June 2019.

ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH HIGH-RISK MYELODISPLASTIC SYNDROMES TREATED WITH INTENSIVE CHEMOTHERAPY: PB2080

Caballero, J. C.; Sánchez, Hernández J. M.; Abáigar, M.; More

HemaSphere. 3:937-938, June 2019.

Author:
Abali, H.

NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY: PS1245

Ferhanoglu, B.; Ozbalak, M.; Bekoz, H.; More

HemaSphere. 3:567-568, June 2019.

Author:
Abarrategi, A.
Author:
Abasov, R.
Author:
Abate, A.
Author:
Abbà, C.
Author:
abbadi, M. R.
Author:
Abbas, H.

RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY: PF205

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3:54-55, June 2019.

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.: S1615

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3:745, June 2019.

Author:
Abbaszadeh, Z.

ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA: S1635

Del Bufalo, F.; Merli, P.; Vinti, L.; More

HemaSphere. 3:755, June 2019.

Author:
Abbati, G.
Author:
Abbenante, M.

A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1: PS997

Cerchione, C.; Guadagnuolo, V.; Papayannidis, C.; More

HemaSphere. 3:448-449, June 2019.

LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE: PB2324

Paolini, S.; Romani, L.; Ottaviani, E.; More

HemaSphere. 3:1036, June 2019.

Author:
Abboud, C.

PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: PS1176

Hochhaus, A.; Gambacorti-Passerini, C.; Abboud, C.; More

HemaSphere. 3:535, June 2019.

Author:
Abboud, M.

IMPACT OF SICKLE CELL DISEASE FROM PATIENTS' AND PHYSICIANS' PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY): PB2300

Osunkwo, I.; Abboud, M.; Andemariam, B.; More

HemaSphere. 3:1026-1027, June 2019.

Author:
Abboud, M. R.

RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE: S147

Vichinsky, E.; Hoppe, C. C.; Ataga, K. I.; More

HemaSphere. 3:25-26, June 2019.

Author:
Abbruzzese, E.

SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED: S123

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3:13-14, June 2019.

Author:
Abby, E.
Author:
Abdallah, A.
Author:
abdallha, A.
Author:
Abdel Azim, S.
Author:
Abdelbary, H.
Author:
Abdelfatah, R.
Author:
Abdelhadi, T.
Author:
Abdelhafeez, A.
Author:
Abdeljelil, N.
Author:
abdellatif, H.
Author:
Abdelmeguid, Y.
Author:
Abdelrahim, M.
Author:
Abdelrahman, H.
Author:
Abdelraouf, R.
Author:
Abdelrazik, A.
Author:
Abdelwahab, M.
Author:
Abdulalimov, E.
Author:
Abdulla, H.
Author:
Abdullaev, A.
Author:
Abdulrahman, S.
Author:
Abe, Y.
Author:
Abedi, M.
Author:
Abella, E.

ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY: PS1391

de la Rubia, J.; Domingo, A.; Delgado, O.; More

HemaSphere. 3:638, June 2019.

PERIPHERAL BLOOD INVOLVEMENT BY FLOW CYTOMETRY IS NOT AN UNUSUAL FEATURE IN IGM MGUS/WALDENSTRÖM MACROGLOBULINEMIA WITH MYD88 L265P MUTATION.: PB2009

Montesdeoca, S.; Calvo, X.; Arenillas, L.; More

HemaSphere. 3:908-909, June 2019.

PRESCRIPTION PATTERNS AND OUTCOMES OF FIRST-LINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA REAL-LIFE PATIENTS ACCORDING TO AGE: A RETROSPECTIVE ANALYSIS OF THE 2012-2016 PERIOD: PB2144

Cejalvo, M. J.; Sureda, A.; González, E.; More

HemaSphere. 3:964-965, June 2019.

Author:
Abello, V.
Author:
Abenhardt, W.
Author:
Abeykoon, J.
Author:
Abeysuriya, V.
Author:
Abhyankar, S.
Author:
Abi Nehme, S.

ENASIDENIB ASSOCIATED WITH IMPROVED SURVIVAL COMPARED WITH STANDARD OF CARE FOR R/R AML PATIENTS WITH AN IDH2 MUTATION BASED ON DATA FROM STUDY AG221-C-001 AND A REVIEW OF PATIENT CHARTS IN FRANCE: PS1026

de Botton, S.; Brandwein, J.; Wei, A.; More

HemaSphere. 3:462-463, June 2019.

TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH IDH2-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA - A FRENCH MEDICAL CHART REVIEW ANALYSIS: PS1041

Pigneux, A.; Quesnel, B.; Thomas, X.; More

HemaSphere. 3:470-471, June 2019.

Author:
Abidin, N. Z.
Author:
Abildgaard, N.

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3: PF626

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3:266-267, June 2019.

POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY: PS1418

Gamberi, B.; Abildgaard, N.; Payer, Ramirez A.; More

HemaSphere. 3:652, June 2019.

CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION: S1602: FOLLOWING SALVAGE ASCT IN MULTIPLE MYELOMA: A RANDOMIZED PHASE 2 TRIAL BY THE NORDIC MYELOMA STUDY GROUP

Gregersen, H.; Peceliunas, V.; Remes, K.; More

HemaSphere. 3:737-738, June 2019.

Author:
Abiodun, M.
Author:
Abo-Elsoaud, A.
Author:
Abonour, R.

EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY: PF601

Chari, A.; Weisel, K. C.; Usmani, S. Z.; More

HemaSphere. 3:254, June 2019.

TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY: PS1384

Jagannath, S.; Narang, M.; Ailawadhi, S.; More

HemaSphere. 3:634, June 2019.

COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US: PS1419

Davies, F.; Rifkin, R.; Costello, C.; More

HemaSphere. 3:652-653, June 2019.

Author:
Abouelnour, A.
Author:
Abougabal, M.
Author:
Aboulfotouh, K.
Author:
Abramova, A.
Author:
Abramova, T.
Show: